London Stock Exchange: RENE
ReNeuron Group Plc produces cell therapy products. It engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. The company's lead therapeutic candidate is ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. It also develops ReN009 stem cell therapy for the treatment of peripheral arterial disease; and ReN003 stem cell therapy program for blindness-causing diseases of the retina, such as retinitis pigmentosa. The company develops and markets a range of stem cell lines, including ReNcell CX and ReNcell VM neural cell lines for use in academic and commercial research in non-therapeutic applications worldwide. ReNeuron Group was founded in 1997 by John David Sinden and is headquartered in Guildford, the United Kingdom.
ReNeuron Group Plc
Surrey Research Park 10 Nugent Road Surrey
Guildford, LO GU2 7AF
SIC Code: 2834